Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

343 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
Preiss D, Giles TD, Thomas LE, Sun JL, Haffner SM, Holman RR, Standl E, Mazzone T, Rutten GE, Tognoni G, Chiang FT, McMurray JJ, Califf RM. Preiss D, et al. Among authors: giles td. Stroke. 2013 Sep;44(9):2590-3. doi: 10.1161/STROKEAHA.113.001177. Epub 2013 Jul 30. Stroke. 2013. PMID: 23899915
Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
Latini R, Staszewsky L, Sun JL, Bethel MA, Disertori M, Haffner SM, Holman RR, Chang F, Giles TD, Maggioni AP, Rutten GE, Standl E, Thomas L, Tognoni G, Califf RM, McMurray JJ. Latini R, et al. Among authors: giles td. Am Heart J. 2013 Nov;166(5):935-40.e1. doi: 10.1016/j.ahj.2013.08.012. Epub 2013 Oct 7. Am Heart J. 2013. PMID: 24176451 Clinical Trial.
Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study.
Wong YW, Thomas L, Sun JL, McMurray JJ, Krum H, Hernandez AF, Rutten GE, Leiter LA, Standl E, Haffner SM, Mazzone T, Martinez FA, Tognoni G, Giles T, Califf RM. Wong YW, et al. Circ Heart Fail. 2013 Mar;6(2):203-10. doi: 10.1161/CIRCHEARTFAILURE.112.000086. Epub 2013 Feb 6. Circ Heart Fail. 2013. PMID: 23388113 Clinical Trial.
Effect of nateglinide on the incidence of diabetes and cardiovascular events.
NAVIGATOR Study Group; Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozár J, Califf RM. NAVIGATOR Study Group, et al. N Engl J Med. 2010 Apr 22;362(16):1463-76. doi: 10.1056/NEJMoa1001122. Epub 2010 Mar 14. N Engl J Med. 2010. PMID: 20228402 Free article. Clinical Trial.
Effect of valsartan on the incidence of diabetes and cardiovascular events.
NAVIGATOR Study Group; McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozár J, Califf RM. NAVIGATOR Study Group, et al. N Engl J Med. 2010 Apr 22;362(16):1477-90. doi: 10.1056/NEJMoa1001121. Epub 2010 Mar 14. N Engl J Med. 2010. PMID: 20228403 Free article. Clinical Trial.
Recurrent stroke in the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial.
Pullicino PM, Qian M, Sacco RL, Freudenberger R, Graham S, Teerlink JR, Mann D, Di Tullio MR, Ponikowski P, Lok DJ, Anker SD, Lip GY, Estol CJ, Levin B, Mohr JP, Thompson JL, Homma S; WARCEF Investigators. Pullicino PM, et al. Cerebrovasc Dis. 2014;38(3):176-81. doi: 10.1159/000365502. Epub 2014 Oct 9. Cerebrovasc Dis. 2014. PMID: 25300706 Free PMC article. Clinical Trial.
Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome.
Drexler AJ, Nesto RW, Abrahamson MJ, Bakris G, Bell D, Brunzell J, Dandona P, Davidson J, Fonseca V, Fowler M, Frye R, Giles T, Haffner S, Hollenberg N, Hsueh W, Law R, Plutzky J, Ratner R, Reusch J, Selwyn A, Sowers J, Wyne K, Young LH. Drexler AJ, et al. Metab Syndr Relat Disord. 2005 Summer;3(2):147-73. doi: 10.1089/met.2005.3.147. Metab Syndr Relat Disord. 2005. PMID: 18370723
343 results